Atlas-backed RNA startup Remix raises another $70M

Less than two years out of the gate, Atlas Venture spinout Remix Therapeutics has bagged another $70M to bring its RNA-targeting drugs into the clinic. The announcement comes amid a difficult funding environment for biotech companies of all shapes and sizes.